MAAVRX
1 known investors
MaavRx is developing a one-time AAV5 gene therapy that delivers the TH and GCH1 genes into putamen neurons so they produce constant levels of L-DOPA, intended as a treatment for patients with advanced Parkinson's disease. The therapy aims to provide lifelong symptom control without the pumps, dyskinesia, and high costs of current continuous L-DOPA infusion.
Investors · 1
Frequently asked questions
- What does MAAVRX do?
- MaavRx is developing a one-time AAV5 gene therapy that delivers the TH and GCH1 genes into putamen neurons so they produce constant levels of L-DOPA, intended as a treatment for patients with advanced Parkinson's disease. The therapy aims to provide lifelong symptom control without the pumps, dyskinesia, and high costs of current continuous L-DOPA infusion.
- Who are MAAVRX's investors?
- MAAVRX's investors include Panacea Venture.